COVID-19 Vaccine Frontrunners and Their Nanotechnology Design
Source abstract
Abstract
Humanity is experiencing a catastrophic pandemic. SARS-CoV-2 has spread globally to cause significant morbidity and mortality, and there still remain unknowns about the biology and pathology of the virus. Even with testing, tracing, and social distancing, many countries are struggling to contain SARS-CoV-2. COVID-19 will only be suppressible when herd immunity develops, either because of an effective vaccine or if the population has been infected and is resistant to reinfection. There is virtually no chance of a return to pre-COVID-19 societal behavior until there is an effective vaccine. Concerted efforts by physicians, academic laboratories, and companies around the world have improved detection and treatment and made promising early steps, developing many vaccine candidates at a pace that has been unmatched for prior diseases. As of August 11, 2020, 28 of these companies have advanced into clinical trials with Moderna, CanSino, the University of Oxford, BioNTech, Sinovac, Sinopharm, Anhui Zhifei Longcom, Inovio, Novavax, Vaxine, Zydus Cadila, Institute of Medical Biology, and the Gamaleya Research Institute having moved beyond their initial safety and immunogenicity studies. This review analyzes these frontrunners in the vaccine development space and delves into their posted results while highlighting the role of the nanotechnologies applied by all the vaccine developers.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: SARS-CoV-2 and COVID-19 Research · SARS-CoV-2 detection and testing · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Bioengineering, University of California San Diego, La Jolla, California 92093, United States
Department of NanoEngineering, University of California San Diego, La Jolla, California 92093, United States
Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire 03755, United States
Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03766, United States
Department of Radiology, University of California San Diego, La Jolla, California 92093, United States
Moores Cancer Center, University of California San Diego, La Jolla, California 92093, United States
Center for Nano-ImmunoEngineering, University of California San Diego, La Jolla, California 92093, United States
Funding
Division of Civil, Mechanical and Manufacturing Innovation
References (100+)
Show source-provided references
1. Cascella M. · 2020
2. 10.1016/j.dsx.2020.04.02010.1016/j.dsx.2020.04.020 ↗
3. WHO Coronavirus Disease (COVID-19) Dashboard https://covid19.who.int (accessed 2020-08-3).
4. Washington, D. of C. 1100 C. A. N. S. 1300B; Dc 20036. PolitiFact - Cuomo Accurately Says that Other Countries that Reopened Saw an Increase in Coronavirus Infections. https://www.politifact.com/factchecks/2020/apr/20/andrew-cuomo/cuomo-accurately-says-other-countries-reopened-saw/ (accessed 2020-08-03).
5. 10.1126/science.abb579310.1126/science.abb5793 ↗
6. 10.1016/j.chom.2020.02.00110.1016/j.chom.2020.02.001 ↗
7. Draft Landscape of COVID-19 Candidate Vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed 2020-08-03).
8. Moderna’s Work on a COVID-19 Vaccine Candidate, Moderna, Inc. https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19 (accessed 2020-08-03).
9. Chinese Clinical Trial Register (ChiCTR) - The World Health Organization International Clinical Trials Registered Organization Registered Platform. http://www.chictr.org.cn/showprojen.aspx?proj=52227 (accessed 2020-05-06).
10. Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-NCoV Vaccine (MRNA-1273) in Healthy Adults - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04283461 (accessed 2020-04-01).
11. 10.1038/s41541-020-0188-310.1038/s41541-020-0188-3 ↗
12. 10.4103/0022-3859.17318710.4103/0022-3859.173187 ↗
13. 10.1038/s41564-020-00789-510.1038/s41564-020-00789-5 ↗
14. 10.4161/rna.2226910.4161/rna.22269 ↗
15. 10.1038/d41586-020-02154-210.1038/d41586-020-02154-2 ↗
16. Thomas K. · New York Times · 2020
17. 10.1056/NEJMoa202248310.1056/NEJMoa2022483 ↗
18. Novavax Announces Positive Phase 1 Data for Its COVID-19 Vaccine Candidate, Novavax Inc. IR Site. https://ir.novavax.com/news-releases/news-release-details/novavax-announces-positive-phase-1-data-its-covid-19-vaccine (accessed 2020-08-06).
19. Mulligan M. J. · medRxiv · 2020 · 2020.06.30.2014
20. Sahin U. · medRxiv · 2020 · 2020.07.17.2014
21. 10.1016/S0140-6736(20)31208-310.1016/S0140-6736(20)31208-3 ↗
22. 10.1016/S0140-6736(20)31605-610.1016/S0140-6736(20)31605-6 ↗
23. 10.1016/S0140-6736(20)31604-410.1016/S0140-6736(20)31604-4 ↗
24. 10.1038/nri280210.1038/nri2802 ↗
25. 10.1016/S1473-3099(10)70049-910.1016/S1473-3099(10)70049-9 ↗
26. 10.1093/cid/ciaa34410.1093/cid/ciaa344 ↗
27. 10.1038/s41577-020-0402-610.1038/s41577-020-0402-6 ↗
28. 10.1038/s41591-020-0995-010.1038/s41591-020-0995-0 ↗
29. 10.3121/cmr.1.2.8710.3121/cmr.1.2.87 ↗
30. 10.1007/978-1-4939-3292-4_110.1007/978-1-4939-3292-4_1 ↗
31. 10.3390/v1004016710.3390/v10040167 ↗
32. 10.1128/CMR.11.3.43010.1128/CMR.11.3.430 ↗
33. 10.3389/fimmu.2013.0018510.3389/fimmu.2013.00185 ↗
34. 10.1016/j.bbi.2020.05.05710.1016/j.bbi.2020.05.057 ↗
35. 10.1586/14760584.2015.108106710.1586/14760584.2015.1081067 ↗
36. 10.4049/jimmunol.160177510.4049/jimmunol.1601775 ↗
37. Altimmune COVID-19 Vaccine Candidate Tested at UAB Shows Positive Preclinical Results - News. https://www.uab.edu/news/research/item/11426-altimmune-covid-19-vaccine-candidate-tested-at-uab-shows-positive-preclinical-results (accessed 2020-08-14).
38. OraPro-COVID-19. Home. https://www.stabilitech.com/orapro-covid-19/ (accessed 2020-08-14).
39. Quadram Researchers Working on COVID-19 Vaccine Join WHO Expert Groups. https://quadram.ac.uk/quadram-researchers-working-on-covid-19-vaccine-join-who-expert-groups/ (accessed Aug 14, 2020).
40. 10.1016/j.biopha.2020.11019510.1016/j.biopha.2020.110195 ↗
41. 10.1016/j.coph.2006.03.00110.1016/j.coph.2006.03.001 ↗
42. 10.1111/j.1471-4159.2008.05723.x10.1111/j.1471-4159.2008.05723.x ↗
43. Wang J. · medRxiv · 2020 · 2020.02.05.2002
44. Charles A Janeway J. · 2001
45. 10.1111/j.1365-2567.2011.03517.x10.1111/j.1365-2567.2011.03517.x ↗
46. 10.3390/vaccines604008410.3390/vaccines6040084 ↗
47. 10.1002/eji.20114185710.1002/eji.201141857 ↗
48. 10.1016/j.jmii.2020.03.01510.1016/j.jmii.2020.03.015 ↗
49. Clinical Stage Pipeline – Novavax – Creating Tomorrow’s Vaccines Today. Novavax.com. https://novavax.com/our-pipeline#nvx-cov2373 (accessed 2020-08-14).
50. 10.1016/j.immuni.2010.10.00210.1016/j.immuni.2010.10.002 ↗
51. 10.1186/1741-7007-8-3710.1186/1741-7007-8-37 ↗
52. 10.1371/journal.pone.004020810.1371/journal.pone.0040208 ↗
53. 10.3390/vaccines801012810.3390/vaccines8010128 ↗
54. 10.3389/fimmu.2018.0222410.3389/fimmu.2018.02224 ↗
55. 10.7150/ntno.1979610.7150/ntno.19796 ↗
56. 10.1126/science.abb250710.1126/science.abb2507 ↗
57. 10.1038/s41590-018-0305-x10.1038/s41590-018-0305-x ↗
58. 10.1089/lrb.2008.100810.1089/lrb.2008.1008 ↗
59. 10.1016/j.addr.2011.05.01710.1016/j.addr.2011.05.017 ↗
60. eTheRNA Launches an International Consortium and Starts Development of Cross-Strain Protective CoV-2 mRNA Vaccine for High Risk Populations. https://finance.yahoo.com/news/etherna-launches-international-consortium-starts-080000668.html (accessed 2020-09-16).
61. B.V, I. Intravacc Partners with Wageningen Bioveterinary Research and Utrecht University to Develop an Intranasal COVID-19 Vaccine. https://www.prnewswire.com/news-releases/intravacc-partners-with-wageningen-bioveterinary-research-and-utrecht-university-to-develop-an-intranasal-covid-19-vaccine-301070721.html (accessed 2020-09-16).
62. 10.1038/s41565-020-0737-y10.1038/s41565-020-0737-y ↗
63. Milken Institute’s COVID-19 Treatment and Vaccine Tracker Tracks the Development of Treatments and Vaccines for COVID-19. https://covid-19tracker.milkeninstitute.org/ (accessed 2020-08-03).
64. 10.1586/erv.12.3810.1586/erv.12.38 ↗
65. 10.1038/ni.203910.1038/ni.2039 ↗
66. 10.3390/vaccines402001210.3390/vaccines4020012 ↗
67. 10.1128/CMR.8.3.40610.1128/CMR.8.3.406 ↗
68. 10.7774/cevr.2013.2.2.9710.7774/cevr.2013.2.2.97 ↗
69. 10.1038/nrmicro224010.1038/nrmicro2240 ↗
70. 10.3390/vaccines203062410.3390/vaccines2030624 ↗
71. 10.1016/j.jconrel.2015.08.00710.1016/j.jconrel.2015.08.007 ↗
72. 10.4161/rna.2020610.4161/rna.20206 ↗
73. 10.1126/science.109362010.1126/science.1093620 ↗
74. 10.3389/fimmu.2019.0059410.3389/fimmu.2019.00594 ↗
75. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04283461 (accessed 2020-04-03).
76. Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates against COVID-19 in Healthy Adults - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04368728 (accessed 2020-05-21).
77. A Multi-Site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines against COVID-2019 Using Different Dosing Regimens in Healthy Adults - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04380701 (accessed 2020-05-21).
78. A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 NCoV-19 in UK Healthy Adult Volunteers - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04324606 (accessed 2020-05-21).
79. Phase I Clinical Trial of a COVID-19 Vaccine in 18–60 Healthy Adults - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04313127 (accessed 2020-05-27).
80. A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04341389 (accessed 2020-05-27).
81. Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04336410 (accessed 2020-04-10).
82. INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19. http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19/default.aspx (accessed 2020-07-21).
83. A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged ≥ 60 Years - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04383574 (accessed 2020-05-21).
84. Sinovac Reports Positive Data from Phase I/II trials of CoronaVac https://www.clinicaltrialsarena.com/news/sinovac-coronavac-data/ (accessed 2020-08-14).
85. China Sinopharm’s Potential COVID-19 Vaccine Triggers Antibodies in Clinical Trials: Journal. Reuters. 2020-08-14.
86. Novel Coronavirus (2019-CoV) Inactivated Vaccine (Vero Cell) Phase I/II Clinical Trial. http://www.chictr.org.cn/showproj.aspx?proj=53003 (accessed 2020-08-14).
87. http://www.chictr.org.cn/showproj.aspx?proj=53003 (accessed 2020-08-14).
88. First COVID-19 Inactivated Vaccine Performs Well in Clinical Trials. http://en.sasac.gov.cn/2020/07/02/c_5178.htm (accessed 2020-08-14).
89. An Open Study of the Safety, Tolerability and Immunogenicity of the Drug “Gam-COVID-Vac” Vaccine against COVID-19 - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04436471 (accessed 2020-08-03).
90. An Open Study of the Safety, Tolerability and Immunogenicity of “Gam-COVID-Vac Lyo” Vaccine against COVID-19 - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04437875 (accessed 2020-08-03).
91. 10.1089/clinomi.07.04.1710.1089/clinomi.07.04.17 ↗
92. Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04445194 (accessed 2020-08-14).
93. A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 RS) with or without MATRIX-MTM Adjuvant in Healthy Subjects - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04368988 (accessed 2020-08-14).
94. Chowdhury D. · Reuters · 2020
95. Monovalent Recombinant COVID19 Vaccine - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04453852 (accessed 2020-08-14).
96. Zydus Cadila’s COVID-19 Vaccine Passes Phase I Safety Trials; Phase II to Test Efficiency Begins 6 August - Health News, Firstpost. https://www.firstpost.com/health/zydus-cadilas-covid-19-vaccine-passes-phase-i-safety-trials-phase-ii-to-test-efficiency-begins-6-august-8674891.html (accessed 2020-08-14).
97. 10.1016/j.virusres.2020.19811410.1016/j.virusres.2020.198114 ↗
98. COVID-19 Vaccine Reaches Phase-2 Trials in China. http://english.nmpa.gov.cn/2020-06/22/c_502093.htm (accessed 2020-08-14).
99. Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing against COVID-19 in People Aged ⩾60 Years - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04470609 (accessed 2020-08-14).
100. 10.1016/j.cell.2017.02.01710.1016/j.cell.2017.02.017 ↗